Guidance
Code Info Sessions
Ethical interactions with the patient community – October 2024
5:42 – Patient centricity and the Code.
27:22 – What does the Code say about patient community interactions?
38:07 – Inviting patient representatives to educational events.
56:07 – Providing information about special access programs.
1:05:34 – Engaging the patient community for PBAC submissions.
1:15:39 – Ethical crunch: clinical trials.
Medicines Australia recognises and supports positive and beneficial relationships between industry and patient organisations. Companies may enter into relationships with patient organisations with the objective of enhancing the quality use of medicines and supporting better health outcomes for the Australian community.
- When entering into relationships with patient organisations, Companies should refer to the Working Together – A Guide to Relationships between Health Consumer Organisations and Pharmaceutical Companies, published on the Medicines Australia website www.medicinesaustralia.com.au.
- Companies should consider on a case-by-case basis whether any offer or proposal to collaborate with, or provide support to a patient organisation or any of its programs is capable of withstanding professional and public scrutiny.
- The selection criteria for sponsorship to enable patients and representatives from a patient organisation to attend third-party scientific and medical conferences should be based on their specific interest in a therapeutic area.
- Companies may share information with patient organisations and their representatives. This may include information about prescription medicines if there is a genuine need for the information, the content is relevant to their specific expertise and interest in the therapeutic area, and is non-promotional.